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Abstract
Early active multiple sclerosis (MS) lesions can be classified histologically into three main immunopathological patterns 
of demyelination (patterns I–III), which suggest pathogenic heterogeneity and may predict therapy response. Patterns I and 
II show signs of immune-mediated demyelination, but only pattern II is associated with antibody/complement deposition. 
In pattern III lesions, which include Baló’s concentric sclerosis, primary oligodendrocyte damage was proposed. Serum 
antibody reactivities could reflect disease pathogenesis and thus distinguish histopathologically defined MS patterns. We 
established a customized microarray with more than 700 peptides that represent human and viral antigens potentially relevant 
for inflammatory demyelinating CNS diseases, and tested sera from 66 patients (pattern I n = 12; II n = 29; III n = 25, includ-
ing 8 with Baló’s), healthy controls, patients with Sjögren’s syndrome and stroke patients. Cell-based assays were performed 
for aquaporin 1 (AQP1) and AQP4 antibody detection. No single peptide showed differential binding among study cohorts. 
Because antibodies can react with different peptides from one protein, we also analyzed groups of peptides. Patients with 
pattern II showed significantly higher reactivities to Nogo-A peptides as compared to patterns I (p = 0.02) and III (p = 0.02). 
Pattern III patients showed higher reactivities to AQP1 (compared to pattern I p = 0.002, pattern II p = 0.001) and varicella 
zoster virus (VZV, compared to pattern II p = 0.05). In patients with Baló’s, AQP1 reactivity was also significantly higher 
compared to patients without Baló’s (p = 0.04), and the former revealed distinct antibody signatures. Histologically, Baló’s 
patients showed loss of AQP1 and AQP4 in demyelinating lesions, but no antibodies binding conformational AQP1 or AQP4 
were detected. In summary, higher reactivities to Nogo-A peptides in pattern II patients could be relevant for enhanced axonal 
repair and remyelination. Higher reactivities to AQP1 peptides in pattern III patients and its subgroup of Baló’s patients 
possibly reflect astrocytic damage. Finally, latent VZV infection may cause peripheral immune activation.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating 
CNS disease with heterogeneous clinical, radiological and 
pathological features that suggest different mechanisms of 
disease development. An accurate diagnosis is important 
from disease onset, as the correct diagnosis has a prognostic 
value and helps inform treatment strategy [9, 18, 25]. How-
ever, the individual disease course, disease progression or 
response to therapies in MS are not yet predictable. Multiple 
drugs are available for MS treatment [56, 57], but we still 
lack biomarkers for stratification of particular subgroups of 
MS patients and specific pathogenic pathways.
Lucchinetti et al. describe three main subgroups of MS 
patients that show different histopathological patterns of 
early active inflammatory demyelinating lesions (patterns 
I–III, Fig. 1) and suggest diverse pathophysiological mecha-
nisms of lesion development [42]. These patterns are stable 
within the individual patient [35, 52] and imply a specific 
and sustained pathogenic pathway for newly developing 
lesions during the entire disease course of that patient. 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-019-02120 -x) contains 
supplementary material, which is available to authorized users.
 * Imke Metz 
 imetz@gwdg.de
Extended author information available on the last page of the article
548 Acta Neuropathologica (2020) 139:547–564
1 3
Pattern I and pattern II lesions show sharply demarcated 
demyelinated areas with inflammation consisting of T cells, 
B cells and macrophages/microglial cells. Yet only in pat-
tern II lesions does the humoral immune system seem to 
be involved in lesion development, as these lesions reveal 
immunoglobulins and complement along myelin sheaths and 
inside macrophages (Fig. 1a–l). In pattern III lesions, oligo-
dendroglial pathology with apoptotic oligodendrocytes and 
subsequent demyelination on an inflammatory background 
is present, suggesting a primary degenerative character of 
lesions [42] (Fig. 1 m–u).
The clinical relevance of these immunopathological pat-
terns has been shown previously: Apheresis is a second-line 
therapy for MS relapses. Whereas pattern III patients do not 
respond to apheresis therapy, > 50% of pattern II patients 
benefit from this treatment [32, 75]. Thus far, patterns I–III 
can only be determined by histopathological analysis of 
brain biopsies. It is apparent that another biomarker would 
be preferable to distinguish these patterns, as well as to bet-
ter understand the immunopathogenesis with the ultimate 
goal of optimizing the treatment of patients.
It is important to note that the immunopathological 
patterns—and thus the heterogeneity of demyelinating 
lesions—are found in early disease stages typically char-
acterized by a relapsing remitting disease course. They can 
only be detected in the earliest lesion stages (early active 
demyelinating lesions) [42, 52]. In contrast, in long estab-
lished MS which is typically characterized by a progres-
sive disease course, chronic active lesions prevail. These 
lesions are usually immunopathologically uniform [6, 21]. 
Antibody- and complement-mediated myelin phagocytosis 
could play a role in demyelination in late disease stages [6].
Furthermore, antibody reactivities were shown to differ 
depending on the disease stage. Distinct antibody patterns, 
based on reactivity to CNS antigens and heat shock proteins, 
were observed in relapsing remitting MS, secondary pro-
gressive MS and primary progressive MS [60]. Antibodies 
directed against α-galactocerebrosides, the major glycolipid 
of CNS myelin, were predominant in relapsing remitting MS 
[50]. In contrast, an increase in circulating anti-ganglioside 
antibodies in primary and secondary progressive MS com-
pared to relapsing–remitting MS has been reported [68]. 
Gangliosides are mainly found in axons. The authors sug-
gested that the transition from relapsing remitting MS to sec-
ondary progressive MS could cause a spread of the immune 
response from myelin to axonal antigens, with the damage of 
axons explaining the progressive disease course [68].
Baló’s concentric sclerosis is a rare MS variant charac-
terized by alternating rings of demyelination and areas of 
myelin preservation [27, 73]. Baló lesions show pattern III 
characteristics featuring MAG loss and apoptotic oligoden-
drocytes (Fig. 2a–c, g). However, astrocytic changes with 
a reduction of aquaporin 4 (AQP4) staining have also been 
described [47]. Radiologically, this type of MS can be iden-
tified by white matter lesions with hyperintense and isoin-
tense concentric lamellae seen on T2-weighted (T2W) and 
sometimes on T1-weighted gadolinium-enhanced (T1 + Gd) 
images [2, 14, 80] (Fig. 2h, i).
Neuromyelitis optica spectrum disorders (NMOSD) were 
the first inflammatory demyelinating diseases characterized 
by specific antibodies [37]. Antibodies directed against the 
water channel AQP4 are used as a diagnostic biomarker 
and play a pathogenic role in lesion development [4, 38, 
82]. Several lines of evidence suggest that antibodies are 
also involved in lesion development in MS [32, 42, 48, 75]. 
Indeed, antibodies binding the myelin oligodendrocyte gly-
coprotein (MOG) were identified in a small subgroup of 
MS patients [22, 63, 72]. However, no specific antibodies 
were otherwise found. It is conceivable that not a single anti-
body, but a specific combination of autoimmune responses 
Fig. 1  Histopathology of the three immunopathological patterns of 
early active inflammatory demyelinating lesions. Histopathological 
characteristics of pattern I lesions (a–f): a demyelinating pattern I 
lesion with a sharp lesion border, as shown with the myelin staining 
luxol fast blue/periodic acid shift (LFB/PAS, myelin shown in blue); 
b the active demyelinating lesion contains numerous of macrophages 
with myelin degradation products incorporated within the cytoplasm 
(PLP staining, major myelin protein, macrophages are filled with 
brown myelin degradation products); c active demyelinating lesion 
also shows numerous MAG-positive macrophages (MAG staining, 
minor myelin protein, macrophages with incorporated myelin degra-
dation products indicated with arrows); d numerous acutely damaged 
axons are present within the lesion (APP staining, small brown dots 
show axonal spheroids); e absence of complement products within 
macrophages in pattern I lesions (negative C9neo staining); f absence 
of IgG deposits within macrophages in pattern I lesions (negative IgG 
staining). Histopathological characteristics of pattern II lesions (g–l): 
g demyelinating pattern II lesion with a sharp lesion border, as indi-
cated with the LFB/PAS staining; h active demyelinating lesion with 
numerous macrophages with PLP-positive degradation products (PLP 
staining) and i MAG-positive macrophages (MAG staining, posi-
tive macrophages indicated with arrows); j some acutely damaged 
axons are seen in the lesion (APP staining); k the hallmark of pattern 
II lesions are activated complement products within macrophages 
(C9neo staining, positive macrophages are indicated with arrows) 
as well as l IgG deposits within macrophages (IgG staining, positive 
macrophages are indicated with arrows), suggesting that the humoral 
immune response plays an important role in lesion development in 
pattern II lesions. Histopathological characteristics of pattern III 
lesions (m–u): m demyelinating pattern III lesion, as indicated with 
LFB/PAS staining; n–o areas of preserved PLP staining show loss 
of CNP expression in the same lesions areas (CNP-loss); p, q areas 
of preserved MOG expression show absence of the MAG expression 
in pattern III lesions (MAG-loss); r, s a reduction and apoptosis of 
oligodendrocytes are further hallmarks of pattern III lesions (NogoA 
staining, apoptotic oligodendrocytes are indicated with arrows); t 
Absence of activated complement products (C9neo staining) and u) 
IgG deposits within macrophages in pattern III lesions. Scale bars: 
a, g and m: 100 µm; b–f, h–l, n–u: 50 µm. PLP proteolipid protein, 
MAG myelin-associated glycoprotein, APP amyloid precursor protein, 
C9neo complement 9neo, IgG immunoglobulin G, CNP 2′,3′-cyclic 
nucleotide 3′-phosphodiesterase, MOG myelin oligodendrocyte gly-
coprotein
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directed against CNS antigens could characterize subgroups 
of MS.
We designed a specific peptide antigen microarray that 
included human and viral antigens of potential relevance 
for inflammatory demyelinating CNS diseases. Peptides 
were preselected from a total of 8,708 peptides containing 
antigens chosen by an extensive literature search as well as 
mimotopes, random epitopes that were used for an unbi-
ased approach (for details see Metz et al. [51]). These pre-
selected peptides, peptides of special interest (e.g. MOG 
peptides) as well as control peptides resulted in a total of 
702 peptides that were used for our customized peptide 
microarray. A full list of included peptides is given in 
Supplementary Table 1, online resource. With this array, 
differential peptide reactivities distinguished between 
NMOSD and relapsing–remitting MS (RRMS) in 80% of 
patients, and also identified higher reactivities to myelin 
and Epstein-Barr virus peptides in relapsing–remitting MS 
(RRMS) compared to NMOSD [51]. In the present study, 
we used this customized peptide microarray to analyze 
specific antibody profiles in different histopathologically 
characterized patterns of MS. These antibody profiles 
may serve as biomarkers and identify potential pathogenic 
mechanisms.
Fig. 2  Typical histopathological and MRI findings in Baló’s concen-
tric sclerosis. a Baló’s lesions are characterized by alternating areas 
of myelin preservation and myelin loss, as indicated with the myelin 
staining luxol fast blue/periodic acid shift (LFB/PAS, myelin shown 
in blue). b Correspondingly, areas of preserved PLP expression and 
areas of PLP loss (PLP staining) can be observed. c A complete loss 
of MAG expression (MAG-loss) in the same lesion areas is found 
and a characteristic feature for pattern III lesions (MAG staining). 
d A subset of Baló’s concentric sclerosis lesions show dystrophic 
astrocytes (GFAP staining), e loss of AQP4 expression (AQP4 stain-
ing) and f loss of AQP1 expression (AQP1 staining). g Notably, a 
reduction of oligodendrocytes in the Baló’s lesions can be observed 
(Olig2 staining, inset with oligodendrocyte loss in higher magnifica-
tion). h MRI shows lesions with T2 hyperintensive alternating con-
centric rings (T2-weighted images) and i concentric rings of contrast 
enhancement (T1 weighted + Gd). Scale bars: a–c: 100  µm; d–g: 
50  µm. PLP proteolipid protein, MAG myelin-associated glycopro-
tein, GFAP glial fibrillary acidic protein, AQP1(4) aquaporin 1(4), Gd 
gadolinium
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Materials and methods
Study cohort and serum sampling
This study was approved by the ethics committee of the 
University Medical Center Göttingen (#19/09/10). Patients 
were recruited at the Institute of Neuropathology, University 
Medical Center Göttingen. Serum samples were all collected 
in the standard manner by the Institute of Neuropathology 
during baseline study examination, except four samples pro-
vided by the Institute of Clinical Neuroimmunology Munich. 
Serum control samples were provided by the Department 
of Neurology, Charité – Universitätsmedizin Berlin. All 
patients gave written informed consent. The study cohort 
included patients with a histopathological diagnosis of 
inflammatory demyelinating lesions consistent with MS 
(referred to as MS patients throughout this manuscript). 
Only patients with biopsies showing early active demyeli-
nating lesions, representing the earliest lesions stages and 
classified into one of the main immunopathological patterns 
I–III, were included in the present study [42]. Brain biopsies 
were performed for clinical differential diagnostics and sent 
to the Institute of Neuropathology for a second opinion. No 
subjects underwent surgery for research purposes. Patients 
with acute disseminated encephalomyelitis (ADEM) [83] 
and NMOSD [10] were excluded from the study.
We analyzed serum from 66 biopsied MS patients (pat-
tern I n = 12; pattern II n = 29; pattern III n = 25), with eight 
of them showing histological and/or MRI characteristics of 
Baló’s concentric sclerosis. Blood sampling was performed 
after a median of 5.7 months (range 0.0–32.3) after the brain 
biopsy. A second blood sample, taken approximately 1 year 
after the first one (median 12.0 months, range 4.8–20.7), 
were available for 30 MS patients (pattern I n = 9, II n = 10, 
III n = 11). Control serum samples were collected from 15 
healthy controls, 15 patients with Sjögren’s syndrome (rep-
resenting a peripheral autoimmune disorder) and 15 patients 
with a stroke (representing a non-inflammatory central nerv-
ous system disease). Stroke patients were diagnosed accord-
ing to the WHO criteria. Patients showed a median stroke 
severity at onset (NIHSS – National Institutes of Health 
Stroke Scale) of 5 (IQR 2–8). Blood was taken after a mean 
of 4.4 days after onset of stroke symptoms. Demographic 
data for control subjects are provided in Supplementary 
Table 2, online resource.
Histological and radiological classification of brain 
lesions
Histopathological classification of brain lesions was per-
formed by two board-certified neuropathologists (WB, 
IM) according to published criteria [42]. Formalin-fixed, 
paraffin-embedded tissue was characterized by histologi-
cal and immunohistochemical stainings presented in Sup-
plementary Table 3, online resource. Only early active 
demyelinating lesions, characterized by the presence of 
macrophages with both minor [2′3′-cyclic nucleotide 3′ 
phosphodiesterase (CNP), myelin-associated glycopro-
tein (MAG), MOG] and major [proteolipid protein (PLP), 
myelin basic protein (MBP)] myelin proteins incorporated 
within the cytoplasm represent the earliest lesion stages 
and can be used for classification into one of the immuno-
pathological patterns I–III [11, 42]. In addition, we clas-
sified patients as having Baló’s concentric sclerosis when 
they showed evidence of concentric demyelination—either 
histologically with repeated areas of concentric myelin 
preservation and loss and/or radiologically with alternat-
ing hyperintense and isointense concentric lamellae seen 
on T2-weighted (T2W) and/or on T1-weighted gadolin-
ium-enhanced (T1 + Gd) sequences [14, 73, 80]. Five 
patients could not certainly be allocated as having Baló’s 
concentric sclerosis or not and were thus excluded from 
the analyses comparing Baló subgroups. Finally, AQP4 
(n = 60), aquaporin 1 (AQP1) (n = 27) and varicella zoster 
virus (VZV, n = 3) immunohistochemistry was performed 
in a subset of patients.
Clinical follow‑up
Clinical data were collected in face-to-face examinations in 
the Institute of Neuropathology and from medical records. 
Diagnosis at the time of blood sampling was based on the 
2017 McDonald criteria for MS [76]. Clinical course was 
classified as single clinical episode (clinically isolated syn-
drome, CIS), relapsing–remitting, secondary progressive or 
primary progressive MS [41]. Expanded disability status 
score (EDSS) at the time of blood sampling was obtained 
during the face-to-face examination (n = 50) or extracted 
from the patients’ clinical records (n = 16).
To analyze possible effects of MS treatments on anti-
body signatures, therapy at the time of blood sampling 
was recorded. Therapies were classified according to their 
assumed effect on immunoglobulin G (IgG) levels in serum 
as (1) reduction of antibody levels probable/shown in prior 
studies, (2) possible/mild reduction of IgG levels and (3) no 
reduction of antibody levels expected. Treatment with high 
dose corticosteroids (HDCS) and plasma exchange (PLEX) 
and/or immunoadsorption (IA) within 1 month before blood 
sampling were considered to likely reduce antibody levels 
[12, 35, 49, 59]. Therapy with rituximab, cyclophosphamide, 
azathioprine, mitoxantrone and teriflunomide was consid-
ered to have a possible effect [40], and treatment with inter-
ferons, dimethyl fumarate, fingolimod, glatiramer acetate, 
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natalizumab and alemtuzumab was assumed to have no 
effect on antibody levels in serum [36, 67].
Additional information about VZV IgG and immuno-
globulin M (IgM) antibody titers in serum and cerebral spi-
nal fluid (CSF), VZV PCR diagnostics in CSF, as well as 
clinical evidence for a herpes zoster infection at the time of 
blood sampling was extracted from the clinical records of 
14 patients with pattern I and III histology.
Peptide microarray
We used a customized peptide microarray setup in prior 
studies that includes 702 peptide antigens representing 
human and viral antigens potentially relevant for inflam-
matory demyelinating diseases, as well as random peptides 
(mimotopes) and controls (for more information see [51] 
and Supplementary Table 1, online resource). Microarrays 
were produced with a peptide laser printer and amino acid 
particles for a combinatorial synthesis of peptides (PEPper-
PRINT, Heidelberg, Germany) [5].
Microarray staining and reading
In short, arrays were incubated with a DyLight 549 conju-
gated goat anti-human immunoglobulin G (IgG) antibody 
(diluted 1:1000; anti-human IgG [H&L] goat antibody, 
Rockland, Gilbertsville, PA) for 30 min and scanned to 
rule out relevant background interactions. Arrays were then 
incubated overnight with serum samples diluted 1:1000, fol-
lowed by staining with the secondary antibody (DyLight 549 
conjugated goat anti-human IgG). C-myc control epitopes 
were printed on the microarray in a square surrounding the 
other peptides and stained with corresponding antibodies 
(chimeric human IgG1 anti-myc (Chi9E10) antibody, pro-
vided by PEPperPRINT, Heidelberg, Germany). The array 
was finally read with a Fujifilm Life Science (Stamford, CT) 
FLA-imaging system using a second harmonic generation 
532 nm (green) diode laser and LPG filter. Quantification 
of spot intensities and peptide annotation were done with 
PepSlide Analyzer (PEPperPRINT). Results are expressed 
as fluorescence intensity units, which reflect the extent of the 
antibody binding to the selected peptide. For more detailed 
information see [51].
Cell‑based AQP1 and AQP4 assay
Cell-based assays (CBA) for AQP1 and AQP4 antibodies 
were performed for selected patients (n = 29), including 
patients with the highest reactivities to AQP1 and AQP4 
peptides as well as all patients with Baló’s concentric scle-
rosis. Patients with Baló’s were included, because a high 
binding of AQP1 peptides was observed in our analyses (see 
results) and because an AQP4-loss in histological sections 
in Baló’s concentric sclerosis patients had previously been 
described [47]. Anti-AQP4 antibodies as identified in cell-
based assays are used for diagnostics in NMOSD.
Analysis of AQP1 antibodies and AQP4 antibodies was 
performed using a live CBA described previously [31, 
44]. Briefly, HEK293A cells were transiently transfected 
using the pcDNA6.2C-EmGFP-GW/TOPO plasmid (Inv-
itrogen, Carlsbad, CA), expressing AQP4 (isoform M23) 
or AQP1 (isoform 1) fused C-terminally to emerald green 
fluorescence protein. Transfected cells were blocked with 
goat IgG in phosphate-buffered saline (PBS)/10% fetal calf 
serum (FCS) (Sigma-Aldrich, St. Louis, MO) followed by 
serum diluted 1:20 and 1:40 in PBS/FCS for 1 h at 4 °C. 
Serum preabsorption with liver powder was not performed. 
Bound antibodies were detected using Cy3Tm-conjugated 
goat anti-human IgG antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA) for 30 min at room tempera-
ture. Bound antibodies were determined using a fluorescence 
microscope (Leica DMI 4000B). All samples were evaluated 
by two independent, clinically blinded investigators who 
agreed on all samples.
Sample size/power calculation
The sample size for this research project was chosen based 
on results from a first validation by Quintana et al. [50]. 
Sample size planning required recruitment of n = 75 patients 
for this purpose, taking possible dropouts also into consid-
eration. A sample size of 25 patients per group provides a 
power of at least 80% for a two-sided t-test at a significance 
level of 5%, as long as the standardized difference between 
groups is at least 0.8. Fisher’s exact test at a two-sided sig-
nificance level of 5% has a power of 94% if the response 
rates in the groups are 25% and 75%, which is a conservative 
estimate.
Statistical analysis
Demographics and clinical characteristics were described by 
summary statistics appropriate for their scales. Group differ-
ences in clinical and expression data were tested using Welch’s 
t test or Wilcoxon test, as appropriate. To test for pairwise 
differences of single peptides, an empirical Bayes method to 
analyze microarray data using linear models to assess differ-
ential expression (limma method) was used. MA plots (i.e., 
Bland–Altman plots) were applied to visualize differential pep-
tide reactivities between pairs of groups. Interactions between 
peptides of a certain subset and patient subgroups were 
assessed with global tests. Global tests were performed accord-
ing to Jung et al. [29] and Goeman et al. [24]. Furthermore, 
to identify groups of peptides showing significantly higher or 
lower antibody reactivities, gene-set-enrichment analyses were 
performed to compare histopathological patterns. For the gene 
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set enrichment analysis, the p-value from the limma method 
for each peptide was used and ranked over all peptides. To 
compare a specific peptide set against the other peptides, a 
Wilcoxon test was applied. Peptide groups which showed sta-
tistically significant differences in both tests were considered 
robust results and are presented here.
Processing of data
Reactivity of duplicate measurements showed a strong corre-
lation of median intensities (r = 0.84), indicating good relia-
bility of results. However, due to inhomogeneous base levels 
of peptide/background reactivities, a normalization of data 
using control peptides spotted on the arrays had to be per-
formed. In a next step, 662 informative peptides, for which 
at least 5% of the participants had normalized intensity val-
ues greater than log2 (1000 arbitrary intensity units), were 
selected for further analyses. When testing within the (high-
dimensional) peptide set was done, Benjamini and Hochberg 
adjustment (fdr) for multiple testing was performed. Due to 
the exploratory character of the study, we did not adjust for 
multiple (patient) group comparisons, and the significance 
threshold was always set at 5%.
Results
Demographic and clinical characteristics of MS 
cohorts
Demographics and basic clinical data of 66 biopsied 
patients, stratified by their immunopathological patterns 
and by their Baló’s concentric sclerosis status, are sum-
marized in Table 1. The groups showed no differences for 
the parameters listed. We focused on early disease stages 
with a median disease duration of less than 1 year. At the 
time of first blood sampling, 29 of 66 patients had clinically 
definitive MS according to the revised McDonald 2017 cri-
teria [76]. More than one-third of the patients (n = 24) were 
being treated with MS-specific therapies at this time point 
(Table 1). Three patients had an acute relapse therapy within 
1 month prior to the blood sampling (HDCS or PLEX/IA). 
One patient was treated with cyclosporine due to liver trans-
plantation and another patient received ipilimumab, an anti-
body targeting cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), to treat melanoma.
Antibody reactivities are more frequent in Sjögren’s 
syndrome (as an example of a peripheral 
autoimmune disease) compared to MS subgroups
First, we aimed to compare antibody reactivities of MS 
patterns I–III with patients with (1) Sjögren’s syndrome 
as an example of a peripheral autoimmune disease with 
known multiple antibody reactivities [17], (2) with stroke 
as an example of a non-autoimmune CNS disease, and (3) 
healthy controls. Antibody reactivities were measured by 
fluorescence intensities which reflect antibody binding to 
the selected peptides.
For this purpose, we compared antibody reactivities to 
single peptides (n = 662). Patients with Sjögren’s syndrome 
showed numerous differentially bound peptides when com-
pared to MS patterns I–III (pattern I n = 225; pattern II 
n = 301; pattern III n = 278 differentially bound peptides, for 
complete list see Supplementary Table 4, online resource). 
Most of the reactivities were higher in Sjögren’s syndrome, 
indicating higher antibody reactivities in this peripheral 
autoimmune disease (compared to pattern I n = 220/225, 
pattern II n = 251/301 and pattern III n = 217/278 peptides 
with higher reactivities in Sjögren’s syndrome). Differen-
tially bound peptides belonged to different proteins, suggest-
ing a broad upregulation of IgG reactivities. In contrast, no 
differentially bound peptides were found when comparing 
MS patterns I–III and stroke patients or healthy controls.
No differences in single peptide reactivities are 
present among MS patterns
Next, we compared the three MS study groups, divided 
according to their immunopathological pattern for differ-
ences in single peptide reactivities; we did not find any 
differentially bound peptides after adjustment for multiple 
testing.
Higher reactivities to AQP1 and VZV peptides are 
found in pattern III patients
We assumed that instead of analyzing reactivities to single 
peptides, reactivities to a group of peptides belonging to one 
protein (for example MOG) or a protein group (for example, 
myelin proteins) could be more informative and potentially 
point to proteins involved in disease pathogenesis. For this 
purpose we compared the IgG reactivities to the following 
peptide groups: Epstein–Barr-Virus (EBV), VZV, cytomeg-
alovirus (CMV), AQP1, AQP4, Nogo-A, all myelin proteins, 
neurofascin, neurofilament, Kir4.1, amyloid beta, contac-
tin-2, AN-2, hypoxia inducible factor 1 alpha (HIF-1α), heat 
shock protein 60 (HSP60), HSP70, and peptides published 
as differentially regulated between patterns I and II by Quin-
tana et al. in 2008 [HSP60, MOG, oligodendrocyte specific 
protein (OSP), PLP] [60].
Higher reactivities directed against the astrocytic water 
channel AQP1 were detected in pattern III patients compared 
to pattern I patients (p values are given for the global tests, 
p < 0.01, Fig. 3a), pattern II patients (p < 0.01, Fig. 3b) and 
healthy controls (p = 0.03, Fig. 3c).
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In accordance with these findings, in some pattern III 
lesions (lesions from Baló’s patients) an AQP1 loss was 
found in demyelinating lesions (see results below and Sup-
plementary Fig. 1, online resource).
To further test AQP1 antibody reactivities, sera with the 
highest binding reactivities found for AQP1 with our peptide 
microarray taken from 19 pattern III lesions (including from 
patients with Baló’s concentric sclerosis) and ten pattern II 
patients without any histological evidence of astrocytopathy 
were tested for antibodies with a cell-based assay recogniz-
ing conformational AQP1 as well as AQP4. No anti-AQP1- 
or anti-AQP4-antibodies were found with this assay.
Also, higher reactivities against VZV peptides were found 
in pattern III patients than in pattern II patients (p = 0.05, 
Fig. 3d). No statistically significant difference was found 
compared to pattern I patients.
No evidence of acute VZV infection was found in pattern 
III patients. We performed immunohistochemical stainings 
for VZV in three pattern III brain biopsies with the highest 
VZV reactivity in our peptide microarray, all with negative 
results. Furthermore, out of 14 pattern III patients with ele-
vated VZV reactivities in our peptide microarray, clinical 
records for evaluation for VZV infection were available from 
11 patients. All patients did not reveal serological and/or 
CSF evidence for acute VZV infection.
Pattern II patients show higher reactivities 
against Nogo‑A peptides
Nogo-A is expressed mostly in oligodendrocytes, but also 
neurons. Pattern II patients showed higher reactivities 
against Nogo-A peptides compared to pattern I patients 
(p = 0.02, Fig. 3e) and pattern III patients (p = 0.02, Fig. 3f).
As Nogo-A antibodies may promote tissue repair, we also 
compared the clinical disability, as measured with the EDSS, 
in pattern II versus pattern I and pattern III patients. At the 
time of blood sampling, a median EDSS of 3.0 was found 
in pattern II patients (with the highest Nogo-A reactivities) 
and of 8.5 in pattern I and pattern III patients (with the low-
est reactivities to Nogo-A peptides), but differences were 
Fig. 3  Binding of selected peptide groups comparing immunopatho-
logical MS patterns and shown with Bland–Altman plots. a–c AQP1 
peptide reactivities in pattern III vs pattern I, II and healthy controls; 
d VZV peptide reactivities in pattern III vs pattern II; e, f NogoA 
peptide reactivities in pattern II vs pattern I and pattern III. Each dot 
represents one peptide. The x-axis displays the average normalized 
signal to show the general level of peptide-binding reactivity. The 
y-axis indicates the differences between the patient groups given as a 
percentage. Greater reactivities in the first-mentioned group are found 
above the 100% horizontal line, and lower reactivities below this line. 
Patients with pattern III lesions showed higher reactivities to AQP1 
peptides as compared to pattern I and II patients as well as healthy 
controls (a–c). These patients also revealed higher binding reactivi-
ties to VZV peptides as compared to pattern II patients (d). Patients 
with pattern II lesions showed higher reactivities to NogoA peptides 
as compared to pattern I and pattern III patients (e, f). AQP1 aqua-
porin 1, VZV varicella zoster virus
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not significant (p = 0.09). Also, no significant differences in 
the median disease duration were seen among these groups.
The differential antibody reactivities to AQP1, VZV and 
Nogo-A peptides comparing immunopathological patterns 
are visualized in Fig. 4a.
Antibody reactivities are not substantially 
influenced by previous medications
As a next step, we investigated possible medication effects 
on IgG reactivities. We excluded three patients with thera-
pies that probably reduce IgG levels in serum (see method 
section, PLEX/IA and HDCS). Our analyses still showed 
no single differentially bound peptides among patterns I-III. 
Analysis of groups of peptides further supported higher 
reactivities of anti-AQP1 and anti-VZV antibodies in pat-
tern III and anti-Nogo-A antibodies in pattern II patients 
(Fig. 4b). We then also excluded nine patients with medi-
cations possibly reducing IgG levels in serum (rituximab, 
cyclophosphamide, azathioprine, mitoxantrone and teriflu-
nomide), with no effect on single peptide reactivities. Dif-
ferences in the antibody binding to AQP1 peptides did not 
change. The binding reactivity to VZV and Nogo-A peptide 
groups was still higher in patterns III and II, but it no longer 
reached statistical significance.
Antibody reactivities in follow‑up blood samples
For a subset of 30 patients, 1-year follow-up serum sam-
ples were available for analysis (pattern I n = 9, pattern 
II n = 10; pattern III n = 11), with a median time interval 
between the first and second sample of 12.0 months (range 
4.8–20.0  months). About half of the patients (n = 14) 
received MS-specific therapies at this time (rituximab n = 3, 
natalizumab n = 3, interferons n = 3, copaxone n = 2, cyclo-
phosphamide n = 2, fingolimod n = 1). The disease course 
changed from CIS to RR MS in one pattern I patient. The 
average correlation index of antibody reactivities between 
Fig. 4  Antibody binding reactivities in three histopathological pat-
terns for AQP1, VZV and Nogo-A peptides, and correlation of these 
antibody reactivities among first and second blood sampling. a Anti-
body reactivities shown as mean normalized fluorescence intensity 
units for AQP1, VZV and Nogo-A peptide groups without correction 
for therapies given before blood sampling (p values of Global test are 
given); b antibody reactivities shown in mean normalized fluores-
cence intensity units for selected peptide groups after correction for 
therapies given before blood sampling: three patients with PLEX/AI 
and/or HDCS therapies that likely reduce IgG levels in serum were 
excluded from analyses (p values of Global test are given); c–e pair-
wise comparison of peptide reactivities between first and second 
blood sample for AQP1, Nogo-A and VZV peptide groups indicated 
by the average correlation index. Reactivities are shown as mean nor-
malized fluorescence intensity units. AQP1 aquaporin 1, VZV vari-
cella zoster virus, PLEX therapeutic plasma exchange, IA immunoad-
sorption, HDCS high dose of corticosteroids
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first and second MS blood samples was r = 0.8, suggesting 
that antibody reactivities are fairly stable over a time period 
of 1 year. AQP1, VZV and NogoA peptide groups showed a 
high average correlation between the first and second blood 
samples (Fig. 4c–e). The comparison of peptide groups in 
follow-up blood samples was hampered by low sample num-
bers: The reactivity against AQP1 peptides was no longer 
higher in pattern III than in pattern II patients (p = 0.07), 
also not compared to pattern I patients (p = 0.86). The most 
stable antibody reactivities were found for VZV peptides 
(r = 0.89, Fig. 4c), which still showed highest reactivities in 
pattern III patients, however without statistical significant 
differences compared to pattern II patients (p = 0.76). For 
Nogo-A peptides the antibody binding reactivities in pattern 
II patients were no longer statistically significant higher than 
in pattern III patients (p = 0.07), also not compared to pattern 
I patients (p = 0.30).
Baló’s concentric sclerosis patients show a distinct 
antibody signature
In a final step, we took another stratification approach and 
compared patients with histological and/or MRI evidence 
of concentric demyelination, indicative of Baló’s concentric 
sclerosis (n = 8) and compared these with MS patients lack-
ing such evidence (n = 53; demographic and basic clinical 
data of cohorts shown in Table 1). Eight pattern III patients 
and none of the patterns I and II patients fulfilled criteria for 
Baló’s concentric sclerosis. Thus, Baló’s concentric sclerosis 
patients comprise a subgroup of pattern III patients.
Analyzing differences in single peptide reactivities, none 
of the peptides showed significantly different binding in 
Baló’s patients after adjustment for multiple testing. Next, 
instead of analyzing single peptides, twenty peptides with 
the most prominent differences between Baló and non-Baló 
patients that included HSP60, AQP1, AQP4, CMV, myelin 
and oligodendrocyte peptides, as well as mimotopes, were 
selected for a heat map, although the single peptides did 
not show significantly different binding after adjustment for 
multiple testing. This heat map showed a clustering of Baló’s 
patients, suggesting a different antibody signature in this 
patient subgroup compared to non-Baló patients (Fig. 5a). 
Also, comparison of heat maps of the twenty peptides with 
the most prominent differences between Baló patients and 
non-Baló pattern III patients showed a clustering of patient 
subgroups (Fig. 5b).
Comparing binding reactivities to different peptide 
groups, Baló’s concentric sclerosis patients showed higher 
binding for AQP1 peptides (p = 0.04 Fig. 5c), as was shown 
beforehand for pattern III versus patterns I and II patients.
Accordingly, we then analyzed a potential AQP1 loss 
in brain sections. Immunohistochemical stainings revealed 
areas of dystrophic astrocytes and simultaneous loss of both 
AQP1 and AQP4 in three out of eight patients with Baló’s 
concentric sclerosis (see Fig.  2d–f and Supplementary 
Fig. 1, online resource). These lesions did not feature any 
other NMO-typical characteristics [10, 65]. None of the non-
Baló’s patients showed a loss of AQP1 or AQP4.
Discussion
We analyzed antibody reactivities to CNS and viral anti-
gens potentially associated with autoimmune inflammatory 
demyelinating diseases, as well as mimotopes in differ-
ent subgroups of MS patients grouped according to their 
histopathologically determined pattern of demyelination 
(patterns I–III). Furthermore, we compared patients with 
Baló’s concentric sclerosis to patients showing inflammatory 
demyelinating lesions, but with no evidence of concentric 
demyelination. Our goal was to identify peptide antibody 
reactivities that distinguish MS subgroups and enhance our 
understanding of disease mechanisms.
Although it is currently unproven whether the different 
histopathological patterns I–III reflect specific etiological 
differences as opposed to different mechanisms of tissue 
injury, evidence from our own work shows that these pat-
terns can be clearly discerned on neuropathological grounds, 
are intraindividually stable, and may thus be associated with 
clinical outcome and therapy response, as has already been 
shown for apheresis treatment [75].
Here we report the largest study of a systematic antibody 
screening in patients with histologically verified immu-
nopathological patterns of MS, as well as in patients with 
Baló’s disease.
When investigating potential biomarkers, it is important 
to take into account the stability of antibody reactivities over 
time. Thus, we analyzed a second serum sample from a rep-
resentative subgroup of our patients (including patterns I, II 
and III patients) after 1 year. Analysis showed a good stabil-
ity of antibody reactivities with a high average correlation 
index of antibody reactivities between first and second MS 
blood samples of r = 0.8.
In our study, patients with pattern III lesions (including 
those with Baló’s concentric sclerosis) showed a higher 
binding to peptides of the water channel AQP1. AQP1 
is widely expressed in diverse tissues, and its expression 
was first described on erythrocytes [3]. Within the CNS it 
is expressed on astrocytes and choroid plexus cells [69]. 
AQP1 immunoreactivity is predominantly localized in the 
white matter and less in the gray matter, subpial, and sub-
ependymal regions as compared to AQP4 [54]. A distinct 
lesion location of pattern III lesions could not be observed 
(data not shown). Also, the subgroup of pattern III patients 
with Baló’s concentric sclerosis showed higher AQP1 reac-
tivities. Antibodies directed against AQP1 (with or without 
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additional AQP4-antibodies) have been found before in 
patients with NMOSD and MS [40, 78, 79], but results could 
not be confirmed when using a cell-based assay [31]. Also in 
our patients, no AQP1 antibodies were detected with a cell-
based assay. Thus, it seems unlikely that the AQP1 antibod-
ies recognize conformational, extracellular epitopes and are 
pathogenic antibodies that cause disease, as shown for AQP4 
antibodies and NMOSD [4, 38]. However, antibodies may 
occur by epitope spreading due to the liberation of astrocytic 
antigens [15, 23, 77]. A sensitization due to recognition of 
peripheral AQP1 antigen also cannot be excluded. The hall-
mark of pattern III lesions is inflammatory demyelination 
associated with oligodendroglial apoptosis and a selective 
loss of the myelin proteins MAG and CNP [42]. In Baló’s 
concentric sclerosis a loss of AQP4 expression on hyper-
trophic astrocytes has been described [47]. Loss of AQP1 
expression was detected in some demyelinated lesions from 
NMO patients [53]. In our study, four out of seven patients 
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with the highest reactivities to AQP1 were classified as Baló 
patients. In a subset of Baló patients, focal areas with an 
AQP1 and AQP4 loss were detected histologically, indicat-
ing astrocytic damage that may have led to epitope spreading 
with antibodies that recognize AQP1 peptides.
How could this astrocytic damage associated with AQP1 
and AQP4 loss be related to oligodendrocyte apoptosis and 
loss of MAG and CNP as is observed in pattern III patients? 
Animal models of NMOSD showed that oligodendroglial 
death rapidly followed astrocytic demise, astrocytic death 
led to secondary demyelination, and oligodendrocyte death 
preceded the infiltration of immune cells [82]. Factors trig-
gered by dying astrocytes such as an increase in extracellular 
glutamate or alterations in the tissue microenvironment due 
to astrocyte loss may cause oligodendroglial death. Thus, 
astrocytic damage in pattern III patients may cause oligo-
dendrocyte metabolic changes which in turn result in MAG 
and CNP loss as well as oligodendrocyte apoptosis, all of 
which are also features of NMOSD lesions [10].
There is an important difference between NMOSD and 
pattern III lesions: in NMOSD, IgG and complement depos-
its are found, but these humoral factors are absent in pattern 
III lesions. Astrocyte dysfunction may also be caused by 
other mechanisms such as lipopolysaccharide (LPS) injec-
tion, which also results in oligodendroglial cell death [70]. 
Interestingly, astrocytic changes were described beforehand 
in MS pattern III lesions and showed similarities to those 
in NMOSD and LPS-induced lesions [70]. The authors 
reported that in NMO lesions, astrocytes were widely 
destroyed, leading to pronounced loss of astrocytes. How-
ever, in MS, astrocyte pathology mainly affected the cell 
processes; damage to astrocytes was minor [70]. In sum-
mary, these observations point to the importance of astrocyte 
functionality for oligodendroglial survival. As in NMOSD, it 
is possible that astrocytic changes are involved in the patho-
genesis of myelin and oligodendrocyte damage in pattern 
III lesions [70, 82].
In our cohort, a higher VZV binding reactivity was also 
evident in pattern III compared to pattern II patients. VZV 
infection has repeatedly been suggested as a trigger of MS 
[71]. Reappearance of VZV DNA in peripheral blood mono-
nuclear cells with an acute MS relapse has been described 
[71]. Moreover, the MRZ reaction (CSF antibodies against 
VZV, measles and rubella) is positive in the majority of 
MS patients [62], and has a prognostic value for conversion 
from CIS to a RR disease course [7]. The MRZ reaction was 
investigated in 267 patients with definite multiple sclerosis, 
and antibodies to VZV were found in 55% [62]. The patho-
physiological significance of this finding is still not clear. 
Also, the question of whether an increased risk of MS is 
associated with varicella and zoster infections remains under 
discussion [45, 46, 66]. Pattern III lesions are characterized 
by an oligodendrocyte apoptosis [42], which together with 
neurons are target cells for VZV infection within the CNS 
[33, 55]. However, we did not find clinical or histological 
evidence of VZV infection in pattern III lesions. Alterna-
tively, it is possible that instead of causing CNS infection, 
latent infection with VZV could trigger peripheral immune 
system activation and thus foster CNS demyelination in a 
subset of MS patients.
Antibodies to CNS antigens may also be beneficial by 
promoting tissue repair. This has been shown for anti-Nogo-
A antibodies. Nogo-A is a known inhibitor of neurite out-
growth, expressed in the CNS on oligodendrocytes, myelin 
and certain neurons. Studying spinal cord injury and stroke 
in animal models, it was shown that the neutralization of 
Nogo-A with antibodies facilitates axonal growth and func-
tional recovery [8, 81]. Using the MS mouse model EAE, 
blocking Nogo-A receptors ameliorated the disease course, 
boosted functional recovery, and increased axonal sprout-
ing and remyelination [28, 30]. Antibodies are thought to 
neutralize inhibitory effects of Nogo-A and thus to activate 
axonal and myelin regeneration. Moreover, Nogo-A antibod-
ies could modulate autoimmune inflammation by switch-
ing T cells to an anti-inflammatory Th2 phenotype [19, 30], 
although it is debated whether this effect is due to targeting 
Nogo-B, which is widely expressed on immune cells, rather 
than Nogo-A [74].
In our study patients with pattern II MS lesions were 
characterized by higher antibody reactivities to Nogo-A 
peptides. Prior studies investigated autoantibody responses 
Fig. 5  Patients with Baló’s concentric sclerosis show a distinct anti-
body signature and higher antibody reactivities to AQP1 peptides 
compared to non-Baló’s patients. a A heat map comparing Baló’s 
concentric sclerosis patients [blue] vs all other multiple sclerosis 
patients [red] is shown. The top 20 peptides from pairwise subgroup 
comparisons are shown as rows (see key for peptides). Patients from 
the two subgroups are shown as columns [red for Baló’s patients, blue 
for non-Baló’s patients]. The color (see key for z score) indicates the 
intensity of the peptide reactivities standardized to healthy controls, 
with blue indicating an upregulation and red a downregulation of 
peptide reactivities, given in standard deviations. The heat map shows 
a clustering of Baló’s patients, suggesting a different antibody signa-
ture in this patient subgroup. b A heat map comparing Baló’s con-
centric sclerosis patients [blue] vs multiple sclerosis patients of pat-
tern III [red] is shown. The top 20 peptides from pairwise subgroup 
comparisons are shown as rows (see key for peptides). Patients from 
the two subgroups are shown as columns [red for Baló’s patients, blue 
for non-Baló’s patients]. The color (see key for z score) indicates the 
intensity of the peptide reactivities standardized to healthy controls, 
with blue indicating an upregulation and red a downregulation of 
peptide reactivities, given in standard deviations. The heat map shows 
a clustering of Baló’s patients, suggesting a different antibody signa-
ture in this patient subgroup. c Antibody reactivities shown as mean 
normalized fluorescence intensity units for AQP1 peptides show a 
higher reactivity in patients with Baló’s concentric sclerosis com-
pared to non-Baló´s patients (p value of Global test is given). EBV 
Epstein–Barr virus, VZV varicella-zoster virus, CMV cytomegalovi-
rus, AQP1 aquaporin 1, AQP4 aquaporin 4, MOG myelin oligoden-
drocyte glycoprotein
◂
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to the large N-terminal domain of Nogo-A and showed 
that Nogo-A IgM antibodies were significantly increased 
in patients with MS and other neurological diseases, but 
not in systemic autoimmune diseases and healthy controls 
[64]. An intrathecal production of Nogo-A IgG antibodies 
has also been shown in MS, and antibodies were higher in 
younger patients and in relapsing–remitting MS as com-
pared to chronic progressive MS [64]. No significant differ-
ences regarding the age at the time of blood sampling or the 
disease course were found when comparing patterns I–III, 
so that these factors do not seem to influence anti-Nogo-A 
antibody levels in our cohorts. Another study showed that 
a substantial proportion of MS patients and also patients 
with other neurological diseases as well as healthy controls 
exhibited serum IgG autoantibodies against the common 
N66 region of Nogo-A [58]. To our knowledge, no studies 
exist that investigated in MS patients whether anti-Nogo-
A antibodies are indeed neutralizing antibodies, although 
Reindl et al. showed in 2002 that at least the antibodies 
recognized Nogo-A in brain extracts, oligodendrocytes and 
cells expressing human Nogo-A [64]. Thus, the biological 
significance of anti-Nogo-A antibodies remains elusive. In 
previous investigations we found less acute axonal damage 
in pattern II than in pattern I and III lesions, which fits well 
with potential axon protective functions of anti-Nogo-A anti-
bodies [26]. However, these observations are preliminary 
and whether anti-Nogo-A antibodies are indeed associated 
with less axonal damage and better clinical outcome has to 
be verified in a larger cohort.
In a second approach, we compared patients with Baló´s 
concentric sclerosis with all other biopsied MS patients. The 
reason for the peculiar demyelination pattern in Baló lesions 
is unclear. It has been suggested that the concentric pattern-
ing is caused by demyelination through histotoxic hypoxia 
alternating with areas protected by tissue preconditioning 
through upregulation of hypoxia inducible factor 1α (HIF1α) 
and heat shock protein 70 (HSP70) [73]. Heatmaps of the 
20 peptides with the most pronounced differences from pair-
wise group comparisons showed differences between Baló’s 
concentric sclerosis patients and the non-Baló MS cohort. 
Peptides included HSP60 and AQP1 as well as AQP4. In 
addition, histology revealed astrocytic damage in a subset 
of Baló patients. These findings support the concept that 
Baló’s concentric sclerosis could represent a unique patho-
logical entity, where pathological changes with a histotoxic 
hypoxia and an upregulation of heat shock proteins, as well 
as astrocytic affection, may play a crucial role in disease 
development.
Our results are based on a cohort of patients with biopsy-
proven inflammatory demyelinating disease and thus carry 
potential biases. However, published evidence suggests 
that findings from biopsied patients can be extrapolated to 
prototypic MS. Despite atypical clinical presentations (i.e., 
tumefactive lesions on MRI; older age), a prior study of 
biopsy cases (n = 91) reported that 90% of patients devel-
oped clinically definite or probable MS during a median 
follow-up of 4.4 years. The clinical course and disability 
during follow-up in the biopsied cohort were indistinguish-
able from the non-biopsied prevalence cohort matched for 
disease duration, age, and sex (n > 200) [59]. In addition, our 
clinical-radiographic study of 168 patients with tumefactive 
biopsied inflammatory demyelinating lesions showed that 
70% developed definite MS at last follow-up, with 83% of 
patients presenting with multiple lesions and 55% fulfill-
ing Barkhof radiographic criteria for MS at the time of last 
MRI [43]. We thus conclude that patients who presented 
with atypical clinical symptoms that led to biopsy never-
theless comprise a representative and informative cohort of 
MS patients.
The short disease duration of patients may be regarded 
as limitation of our study. However, as mentioned above, 
most patients do develop typical MS during follow-up. We 
consider early disease stages to be optimal for investigating 
the initial mechanisms that lead to lesion formation, and par-
ticularly in these stages it is possible to observe inter-indi-
vidual lesion heterogeneity. Antigen microarrays have been 
successfully used in numerous studies on demyelinating 
autoimmune diseases, including MS for analysis of disease-
specific antibodies and distinction of patient subgroups [51, 
60, 84]. Still, the linearity of peptides is clearly an important 
limitation of our study. Post-transcriptional conformational 
changes in the proteins are important for antibody recogni-
tion and binding. Autologous proteins may become immuno-
genic if they are structurally modified post-translationally by 
transglutamination, deamidation, glycosylation, oxidation, 
nitration or proteolytic cleavage [1]. We cannot exclude the 
possibility that we missed antibody reactivities that only 
recognize conformational and post-translationally modified 
epitopes. Also, we cannot exclude multispecificity of anti-
body reactivities. In addition, a relatively small number of 
participants in each group may be regarded as a limitation 
of the study. We could not increase patient numbers in the 
study due to the limited number of biopsied MS patients. 
Nevertheless, this study is the largest systemic antibody 
screening in patients with detailed histological characteri-
zation. We ruled out that prior immunosuppressive/immu-
nomodulatory treatment influenced our results.
Although antibody signatures do not allow allocation 
of single patients to patterns I–III or Baló’s concentric 
sclerosis, our findings explain some of the heterogeneity 
of MS lesion pathology by showing characteristic anti-
body reactivities that may help understand the pathogenic 
mechanisms of lesion development. The present data 
provide further evidence that Baló’s concentric sclerosis 
may be a distinct disease entity. Better identification and 
characterization of MS patient subgroups, based on their 
561Acta Neuropathologica (2020) 139:547–564 
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assumed pathogenesis, will allow more personalized MS 
patient care.
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